IDEXX Laboratories Announces Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/31/2026
- Wall Street ends sharply higher, lifted by soaring Microsoft
- Microsoft surges 8% on strong revenue outlook, maintained capex guidance
- Meta sinks 8% after Q3 revenue forecast misses Wall Street estimates
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Microsoft rally lifts stocks, 30-year Treasury yield hits 19-year peak
- Wall Street ends sharply higher, lifted by soaring Microsoft
- KBR names its Mission Technology Solutions spinoff Trinzic
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- Altria Group (MO) Misses Q2 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
- Rivian Automotive (RIVN) Tops Q2 EPS by 20c, Tops on Revenue; Delivers 12,194 EVs
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Northcoast Research Upgrades IDEXX Laboratories (IDXX) to Neutral
August 3, 2016 9:32 AM EDTNorthcoast Research upgraded IDEXX Laboratories (NASDAQ: IDXX) from Sell to Neutral.
For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.
Shares of IDEXX Laboratories closed at $105.88 yesterday.
... MoreIDEXX Laboratories (IDXX) PT Raised to $120 at Stifel on 'Very Impressive' Q2
August 2, 2016 1:26 PM EDTStifel Buy analyst Jonathan Block reiterated a Buy rating and raised his price target on IDEXX Laboratories (NASDAQ: IDXX) to $120.00 (from $92.00) following "very impressive" 2Q16 results with revenue of $467MM and EPS of $0.74, well above our $447MM and $0.61 estimates.
Block commented, "Management raised 2016... More
IDEXX Labs (IDXX) Tops Q2 EPS by 12c; Raises Outlook
August 2, 2016 7:04 AM EDTIDEXX Labs (NASDAQ: IDXX) reported Q2 EPS of $0.74, $0.12 better than the analyst estimate of $0.62. Revenue for the quarter came in at $467 million versus the consensus estimate of $444.83 million.
GUIDANCE:
IDEXX Labs sees FY2016 EPS of $2.32-$2.39, versus the consensus of $2.21.
"We accelerated growth in the second quarter, further demonstrating the benefits of bringing our innovations to an attractive global market with an expanded commercial presence, including our move to a fully-direct sales strategy in the US companion animal market in 2015," said Jonathan Ayers, the Company's Chairman and... More
